These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 34108170)

  • 1. Evaluation of risk mitigation measures for people with substance use disorders to address the dual public health crises of COVID-19 and overdose in British Columbia: a mixed-method study protocol.
    Nosyk B; Slaunwhite A; Urbanoski K; Hongdilokkul N; Palis H; Lock K; Min JE; Zhao B; Card KG; Barker B; Meilleur L; Burmeister C; Thomson E; Beck-McGreevy P; Pauly B
    BMJ Open; 2021 Jun; 11(6):e048353. PubMed ID: 34108170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of pharmaceutical alternatives to a toxic drug supply in British Columbia: A mixed methods study.
    Pauly BB; Kurz M; Dale LM; Macevicius C; Kalicum J; Pérez DG; McCall J; Urbanoski K; Barker B; Slaunwhite A; Lindsay M; Nosyk B
    J Subst Use Addict Treat; 2024 Jun; 161():209341. PubMed ID: 38490334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Risk Mitigation Guidance opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort study.
    Slaunwhite A; Min JE; Palis H; Urbanoski K; Pauly B; Barker B; Crabtree A; Bach P; Krebs E; Dale L; Meilleur L; Nosyk B
    BMJ; 2024 Jan; 384():e076336. PubMed ID: 38199614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "It's just a perfect storm": Exploring the consequences of the COVID-19 pandemic on overdose risk in British Columbia from the perspectives of people who use substances.
    Foreman-Mackey A; Xavier J; Corser J; Fleury M; Lock K; Mehta A; Lamb J; McDougall J; Newman C; Buxton JA
    BMC Public Health; 2023 Apr; 23(1):640. PubMed ID: 37013524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid Coprescription Through Risk Mitigation Guidance and Opioid Agonist Treatment Receipt.
    Min JE; Guerra-Alejos BC; Yan R; Palis H; Barker B; Urbanoski K; Pauly B; Slaunwhite A; Bach P; Ranger C; Heaslip A; Nosyk B
    JAMA Netw Open; 2024 May; 7(5):e2411389. PubMed ID: 38748421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk mitigation guidance and safer supply prescribing among young people who use drugs in the context of COVID-19 and overdose emergencies.
    Giang K; Charlesworth R; Thulien M; Mulholland A; Barker B; Brar R; Pauly B; Fast D
    Int J Drug Policy; 2023 May; 115():104023. PubMed ID: 37059025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of co-occurring mental illness and substance use disorder and association with overdose: a linked data cohort study among residents of British Columbia, Canada.
    Keen C; Kinner SA; Young JT; Jang K; Gan W; Samji H; Zhao B; Krausz M; Slaunwhite A
    Addiction; 2022 Jan; 117(1):129-140. PubMed ID: 34033179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doing community-based research during dual public health emergencies (COVID and overdose).
    Beck McGreevy P; Wood S; Thomson E; Burmeister C; Spence H; Pelletier J; Giesinger W; McDougall J; McLeod R; Hutchison A; Lock K; Norton A; Barker B; Urbanoski K; Slaunwhite A; Nosyk B; Pauly B
    Harm Reduct J; 2023 Sep; 20(1):135. PubMed ID: 37715202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of evidence to guide decision-making during the COVID-19 pandemic: divergent perspectives from a qualitative case study in British Columbia, Canada.
    Brubacher LJ; Lovato CY; Sriram V; Cheng M; Berman P
    Health Res Policy Syst; 2024 Jun; 22(1):66. PubMed ID: 38831457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overdose deaths and the COVID-19 pandemic in British Columbia, Canada.
    Palis H; Bélair MA; Hu K; Tu A; Buxton J; Slaunwhite A
    Drug Alcohol Rev; 2022 May; 41(4):912-917. PubMed ID: 34908203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using intervention mapping to develop 'ROSE': an intervention to support peer workers in overdose response settings.
    Mamdani Z; McKenzie S; Cameron F; Knott M; Conway-Brown J; Scott T; Buxton JA; Pauly B
    BMC Health Serv Res; 2021 Nov; 21(1):1279. PubMed ID: 34838019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increases in housing rules and surveillance during COVID-19: impacts on overdose and overdose response in a community-based cohort of sex workers who use drugs in Vancouver, BC.
    McDermid J; Pearson J; Braschel M; Moreheart S; Marck R; Shannon K; Krüsi A; Goldenberg SM
    Harm Reduct J; 2024 Aug; 21(1):153. PubMed ID: 39175071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing mortality from covid-19 to mortality due to overdose: A micromort analysis.
    Lee Y; Lui LMW; Brietzke E; Liao Y; Lu C; Ho R; Subramaniapillai M; Mansur RB; Rosenblat JD; McIntyre RS
    J Affect Disord; 2022 Jan; 296():514-521. PubMed ID: 34656039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with 60-day adherence to "safer supply" opioids prescribed under British Columbia's interim clinical guidance for health care providers to support people who use drugs during COVID-19 and the ongoing overdose emergency.
    Selfridge M; Card K; Kandler T; Flanagan E; Lerhe E; Heaslip A; Nguyen A; Moher M; Pauly B; Urbanoski K; Fraser C
    Int J Drug Policy; 2022 Jul; 105():103709. PubMed ID: 35525052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low awareness of risk mitigation prescribing in response to dual crises of COVID-19 and overdose deaths among people who use unregulated drugs in Vancouver, Canada.
    Moshkforoush M; DeBeck K; Brar R; Fairbairn N; Cui Z; Milloy MJ; Buxton J; Oldenburger T; McLellan W; Kendall P; Sedgemore K; Wilson D; Kerr T; Hayashi K
    Harm Reduct J; 2022 May; 19(1):50. PubMed ID: 35614440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "It's an emotional roller coaster… But sometimes it's fucking awesome": Meaning and motivation of work for peers in overdose response environments in British Columbia.
    Pauly BB; Mamdani Z; Mesley L; McKenzie S; Cameron F; Edwards D; Howell A; Knott M; Scott T; Seguin R; Greer AM; Buxton JA
    Int J Drug Policy; 2021 Feb; 88():103015. PubMed ID: 33176249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of Safe Supply Alternatives During Intersecting COVID-19 and Overdose Health Emergencies in British Columbia, Canada, 2021.
    McNeil R; Fleming T; Mayer S; Barker A; Mansoor M; Betsos A; Austin T; Parusel S; Ivsins A; Boyd J
    Am J Public Health; 2022 Apr; 112(S2):S151-S158. PubMed ID: 35262376
    [No Abstract]   [Full Text] [Related]  

  • 18. People who use drugs' prioritization of regulation amid decriminalization reforms in British Columbia, Canada: A qualitative study.
    Xavier JC; McDermid J; Buxton J; Henderson I; Streukens A; Lamb J; Greer A
    Int J Drug Policy; 2024 Mar; 125():104354. PubMed ID: 38402802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feeling safer: effectiveness, feasibility, and acceptability of continuous pulse oximetry for people who smoke opioids at overdose prevention services in British Columbia, Canada.
    Moe J; Chavez T; Marr C; Cameron F; Feldman-Kiss D; Wang YE; Xavier JC; Mamdani Z; Purssell RA; Salmon A; Buxton JA
    Harm Reduct J; 2024 Feb; 21(1):45. PubMed ID: 38378610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 and overdose prevention: Challenges and opportunities for clinical practice in housing settings.
    MacKinnon L; Socías ME; Bardwell G
    J Subst Abuse Treat; 2020 Dec; 119():108153. PubMed ID: 33032862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.